Information on safety and efficacy of systemic treatment in patients with hepatocellular carcinoma under dialysis are limited due to patient exclusion from clinical trials. Thus, we aimed to evaluate the rate, prevalence, tolerability, and outcome of sorafenib in this population.
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis
Giannini, Edoardo G;
2020-01-01
Abstract
Information on safety and efficacy of systemic treatment in patients with hepatocellular carcinoma under dialysis are limited due to patient exclusion from clinical trials. Thus, we aimed to evaluate the rate, prevalence, tolerability, and outcome of sorafenib in this population.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Liver Int & sorafenib in CKD.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
723.57 kB
Formato
Adobe PDF
|
723.57 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
